🇺🇸 FDA
Pipeline program

HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies

APHP191116

Phase 1 other active

Quick answer

HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies for hematologic malignancies ; acute myeloid leukemias is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
hematologic malignancies ; acute myeloid leukemias
Phase
Phase 1
Modality
other
Status
active

Clinical trials